Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Bimzelx® (bimekizumab-bkzx) – New indication
November 20, 2024 - UCB announced the FDA approval of Bimzelx (bimekizumab-bkzx), for the treatment of adults with moderate to severe hidradenitis suppurativa.
